You know who manages cancer spend and prevents this from happening (while delivering quality care)? $STLN.
Solution to a big problem for patients and payers.
$AIRS procedures feature prominently in American Society of Plastic Surgeons annual report. Reading this highlights how it is only a matter of time before $AIRS capitalizes on these GLP-1-driven trends in a major way.
Probably wrong, definitely not financial advice.
No offense to these folks, but the number of # I got on $STLN today along the lines of “OMG, FL is suing PBMs” and “OMG, Trump is cutting drug prices” just shows me the biz model is still misunderstood…and we are going a lot higher as people figure it out.
Specialty pharmacies
Very important development for $STIM this week, as a VC-back interventional psychiatry start-up acquired the second largest network in the country ($STIM operates the largest).
Suddenly with multiple VC platforms interested in the space, the $7-10 / share valuation framework in
He ain’t wrong, also imo. $AIRS catalyst watch:
- debt refi any week now
- conference appearance (lots upcoming) updates on new marketing ROI / new procedure traction
- potential insider buys, valuation here is crazy
- new analyst coverage (couple of new analysts on the call)
$CRM and the rest of software showing you companies are benefiting from deploying AI.
Guess which healthcare subsector has the most to gain? Probably diagnostics like $XGN and $BDSX.
If fact, $XGN already has a robust AI effort supporting biopharma and therapy development for
Now that $CRM has told us that software is not, in fact, dead… I would like to make another observation that is probably wrong and certainly not financial advice: $CCLD seems like a no brainer.
They basically offer billing software for very small (sub-10 doctor) healthcare